Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 1429 entries
Sorted by: Best Match Show Resources per page
Production of (177)Lu for Targeted Radionuclide Therapy: Available Options.

Nuclear medicine and molecular imaging

Dash A, Pillai MR, Knapp FF.
PMID: 26085854
Nucl Med Mol Imaging. 2015 Jun;49(2):85-107. doi: 10.1007/s13139-014-0315-z. Epub 2015 Feb 17.

BACKGROUND: This review provides a comprehensive summary of the production of (177)Lu to meet expected future research and clinical demands. Availability of options represents the cornerstone for sustainable growth for the routine production of adequate activity levels of (177)Lu...

Cite
Dash A, Pillai MR, Knapp FF. Production of (177)Lu for Targeted Radionuclide Therapy: Available Options. Nucl Med Mol Imaging. 2015;49(2):85-107doi: 10.1007/s13139-014-0315-z.
Dash, A., Pillai, M. R., & Knapp, F. F. (2015). Production of (177)Lu for Targeted Radionuclide Therapy: Available Options. Nuclear medicine and molecular imaging, 49(2), 85-107. https://doi.org/10.1007/s13139-014-0315-z
Dash, Ashutosh, et al. "Production of (177)Lu for Targeted Radionuclide Therapy: Available Options." Nuclear medicine and molecular imaging vol. 49,2 (2015): 85-107. doi: https://doi.org/10.1007/s13139-014-0315-z
Dash A, Pillai MR, Knapp FF. Production of (177)Lu for Targeted Radionuclide Therapy: Available Options. Nucl Med Mol Imaging. 2015 Jun;49(2):85-107. doi: 10.1007/s13139-014-0315-z. Epub 2015 Feb 17. PMID: 26085854; PMCID: PMC4463871.
Copy Download .nbib Format: NLM
Pharmacokinetic modeling of [(18)F]fluorodeoxyglucose (FDG) for premature infants, and newborns through 5-year-olds.

EJNMMI research

Khamwan K, Plyku D, O'Reilly SE, Goodkind A, Cao X, Fahey FH, Treves ST, Bolch WE, Sgouros G.
PMID: 26988861
EJNMMI Res. 2016 Dec;6(1):28. doi: 10.1186/s13550-016-0179-6. Epub 2016 Mar 17.

BACKGROUND: Absorbed dose estimates for pediatric patients require pharmacokinetics that are, to the extent possible, age-specific. Such age-specific pharmacokinetic data are lacking for many of the diagnostic agents typically used in pediatric imaging. We have developed a pharmacokinetic model...

Cite
Khamwan K, Plyku D, O'Reilly SE, et al. Pharmacokinetic modeling of [(18)F]fluorodeoxyglucose (FDG) for premature infants, and newborns through 5-year-olds. EJNMMI Res. 2016;6(1):28doi: 10.1186/s13550-016-0179-6.
Khamwan, K., Plyku, D., O'Reilly, S. E., Goodkind, A., Cao, X., Fahey, F. H., Treves, S. T., Bolch, W. E., & Sgouros, G. (2016). Pharmacokinetic modeling of [(18)F]fluorodeoxyglucose (FDG) for premature infants, and newborns through 5-year-olds. EJNMMI research, 6(1), 28. https://doi.org/10.1186/s13550-016-0179-6
Khamwan, Kitiwat, et al. "Pharmacokinetic modeling of [(18)F]fluorodeoxyglucose (FDG) for premature infants, and newborns through 5-year-olds." EJNMMI research vol. 6,1 (2016): 28. doi: https://doi.org/10.1186/s13550-016-0179-6
Khamwan K, Plyku D, O'Reilly SE, Goodkind A, Cao X, Fahey FH, Treves ST, Bolch WE, Sgouros G. Pharmacokinetic modeling of [(18)F]fluorodeoxyglucose (FDG) for premature infants, and newborns through 5-year-olds. EJNMMI Res. 2016 Dec;6(1):28. doi: 10.1186/s13550-016-0179-6. Epub 2016 Mar 17. PMID: 26988861; PMCID: PMC4797375.
Copy Download .nbib Format: NLM
Basic Sciences of Nuclear Medicine.

Medical physics

Zanzonico P.
PMID: 28524975
Med Phys. 2011 Sep;38(9):5265-5266. doi: 10.1118/1.3626488.

No abstract available.

Cite
Zanzonico P. Basic Sciences of Nuclear Medicine. Med Phys. 2011;38(9):5265-5266doi: 10.1118/1.3626488.
Zanzonico, P. (2011). Basic Sciences of Nuclear Medicine. Medical physics, 38(9), 5265-5266. https://doi.org/10.1118/1.3626488
Zanzonico, Pat. "Basic Sciences of Nuclear Medicine." Medical physics vol. 38,9 (2011): 5265-5266. doi: https://doi.org/10.1118/1.3626488
Zanzonico P. Basic Sciences of Nuclear Medicine. Med Phys. 2011 Sep;38(9):5265-5266. doi: 10.1118/1.3626488. PMID: 28524975.
Copy Download .nbib Format: NLM
Positron Emission Tomography in Breast Cancer.

Diagnostics (Basel, Switzerland)

Vercher-Conejero JL, Pelegrí-Martinez L, Lopez-Aznar D, Cózar-Santiago Mdel P.
PMID: 26854143
Diagnostics (Basel). 2015 Mar 16;5(1):61-83. doi: 10.3390/diagnostics5010061.

Gradually, FDG-PET/CT has been strengthening within the diagnostic algorithms of oncological diseases. In many of these, PET/CT has shown to be useful at different stages of the disease: diagnosis, staging or re-staging, treatment response assessment, and recurrence. Some of...

Cite
Vercher-Conejero JL, Pelegrí-Martinez L, Lopez-Aznar D, et al. Positron Emission Tomography in Breast Cancer. Diagnostics (Basel). 2015;5(1):61-83doi: 10.3390/diagnostics5010061.
Vercher-Conejero, J. L., Pelegrí-Martinez, L., Lopez-Aznar, D., & Cózar-Santiago, M. d. e. l. . P. (2015). Positron Emission Tomography in Breast Cancer. Diagnostics (Basel, Switzerland), 5(1), 61-83. https://doi.org/10.3390/diagnostics5010061
Vercher-Conejero, Jose Luis, et al. "Positron Emission Tomography in Breast Cancer." Diagnostics (Basel, Switzerland) vol. 5,1 (2015): 61-83. doi: https://doi.org/10.3390/diagnostics5010061
Vercher-Conejero JL, Pelegrí-Martinez L, Lopez-Aznar D, Cózar-Santiago Mdel P. Positron Emission Tomography in Breast Cancer. Diagnostics (Basel). 2015 Mar 16;5(1):61-83. doi: 10.3390/diagnostics5010061. PMID: 26854143; PMCID: PMC4665546.
Copy Download .nbib Format: NLM
Production, biodistribution assessment and dosimetric evaluation of (177)Lu-TTHMP as an agent for bone pain palliation.

Asia Oceania journal of nuclear medicine & biology

Zolghadri S, Yousefnia H, Jalilian AR, Ghannadi-Maragheh M.
PMID: 27408879
Asia Ocean J Nucl Med Biol. 2015;3(1):35-42.

OBJECTIVES: Recently, bone-avid radiopharmaceuticals have been shown to have potential benefits for the treatment of widespread bone metastases. Although (177)Lu-triethylene tetramine hexa methylene phosphonic acid (abbreviated as (177)Lu-TTHMP), as an agent for bone pain palliation, has been evaluated in...

Cite
Zolghadri S, Yousefnia H, Jalilian AR, et al. Production, biodistribution assessment and dosimetric evaluation of (177)Lu-TTHMP as an agent for bone pain palliation. Asia Ocean J Nucl Med Biol. 2015;3(1):35-42
Zolghadri, S., Yousefnia, H., Jalilian, A. R., & Ghannadi-Maragheh, M. (2015). Production, biodistribution assessment and dosimetric evaluation of (177)Lu-TTHMP as an agent for bone pain palliation. Asia Oceania journal of nuclear medicine & biology, 3(1), 35-42.
Zolghadri, Samaneh, et al. "Production, biodistribution assessment and dosimetric evaluation of (177)Lu-TTHMP as an agent for bone pain palliation." Asia Oceania journal of nuclear medicine & biology vol. 3,1 (2015): 35-42.
Zolghadri S, Yousefnia H, Jalilian AR, Ghannadi-Maragheh M. Production, biodistribution assessment and dosimetric evaluation of (177)Lu-TTHMP as an agent for bone pain palliation. Asia Ocean J Nucl Med Biol. 2015;3(1):35-42. PMID: 27408879; PMCID: PMC4937688.
Copy Download .nbib Format: NLM
Newer positron emission tomography radiopharmaceuticals for radiotherapy planning: an overview.

Annals of translational medicine

Sharma P, Mukherjee A.
PMID: 26904575
Ann Transl Med. 2016 Feb;4(3):53. doi: 10.3978/j.issn.2305-5839.2016.01.26.

Positron emission tomography-computed tomography (PET-CT) has changed cancer imaging in the last decade, for better. It can be employed for radiation treatment planning of different cancers with improved accuracy and outcomes as compared to conventional imaging methods. (18)F-fluorodeoxyglucose remains...

Cite
Sharma P, Mukherjee A. Newer positron emission tomography radiopharmaceuticals for radiotherapy planning: an overview. Ann Transl Med. 2016;4(3):53doi: 10.3978/j.issn.2305-5839.2016.01.26.
Sharma, P., & Mukherjee, A. (2016). Newer positron emission tomography radiopharmaceuticals for radiotherapy planning: an overview. Annals of translational medicine, 4(3), 53. https://doi.org/10.3978/j.issn.2305-5839.2016.01.26
Sharma, Punit, and Mukherjee, Anirban. "Newer positron emission tomography radiopharmaceuticals for radiotherapy planning: an overview." Annals of translational medicine vol. 4,3 (2016): 53. doi: https://doi.org/10.3978/j.issn.2305-5839.2016.01.26
Sharma P, Mukherjee A. Newer positron emission tomography radiopharmaceuticals for radiotherapy planning: an overview. Ann Transl Med. 2016 Feb;4(3):53. doi: 10.3978/j.issn.2305-5839.2016.01.26. PMID: 26904575; PMCID: PMC4739998.
Copy Download .nbib Format: NLM
Radiotherapy to volumes defined by metabolic imaging in gliomas: time to abandon monstrous margins?.

Annals of translational medicine

Susheela SP, Revannasiddaiah S.
PMID: 26904577
Ann Transl Med. 2016 Feb;4(3):55. doi: 10.3978/j.issn.2305-5839.2016.01.19.

The survival in patients with high grade gliomas (HGG) remains poor even after the adoption post-operative radiotherapy (RT) to magnetic resonance imaging (MRI) based volumes. Despite delivery of 'standardized' doses of radiation, recurrence is the norm, rather than the...

Cite
Susheela SP, Revannasiddaiah S. Radiotherapy to volumes defined by metabolic imaging in gliomas: time to abandon monstrous margins?. Ann Transl Med. 2016;4(3):55doi: 10.3978/j.issn.2305-5839.2016.01.19.
Susheela, S. P., & Revannasiddaiah, S. (2016). Radiotherapy to volumes defined by metabolic imaging in gliomas: time to abandon monstrous margins?. Annals of translational medicine, 4(3), 55. https://doi.org/10.3978/j.issn.2305-5839.2016.01.19
Susheela, Sridhar P, and Revannasiddaiah, Swaroop. "Radiotherapy to volumes defined by metabolic imaging in gliomas: time to abandon monstrous margins?." Annals of translational medicine vol. 4,3 (2016): 55. doi: https://doi.org/10.3978/j.issn.2305-5839.2016.01.19
Susheela SP, Revannasiddaiah S. Radiotherapy to volumes defined by metabolic imaging in gliomas: time to abandon monstrous margins?. Ann Transl Med. 2016 Feb;4(3):55. doi: 10.3978/j.issn.2305-5839.2016.01.19. PMID: 26904577; PMCID: PMC4740003.
Copy Download .nbib Format: NLM
FIBT versus florbetaben and PiB: a preclinical comparison study with amyloid-PET in transgenic mice.

EJNMMI research

Yousefi BH, von Reutern B, Scherübl D, Manook A, Schwaiger M, Grimmer T, Henriksen G, Förster S, Drzezga A, Wester HJ.
PMID: 25918674
EJNMMI Res. 2015 Mar 28;5:20. doi: 10.1186/s13550-015-0090-6. eCollection 2015.

BACKGROUND: Over the last decade, an increasing number of studies have been published on the use of amyloid-β (Aβ) PET imaging with different (18)F-radiopharmaceuticals for clinical characterization of Alzheimer's disease (AD) in different stages. However, distinct study cohorts and...

Cite
Yousefi BH, von Reutern B, Scherübl D, et al. FIBT versus florbetaben and PiB: a preclinical comparison study with amyloid-PET in transgenic mice. EJNMMI Res. 2015;5:20doi: 10.1186/s13550-015-0090-6.
Yousefi, B. H., von Reutern, B., Scherübl, D., Manook, A., Schwaiger, M., Grimmer, T., Henriksen, G., Förster, S., Drzezga, A., & Wester, H. J. (2015). FIBT versus florbetaben and PiB: a preclinical comparison study with amyloid-PET in transgenic mice. EJNMMI research, 520. https://doi.org/10.1186/s13550-015-0090-6
Yousefi, Behrooz H, et al. "FIBT versus florbetaben and PiB: a preclinical comparison study with amyloid-PET in transgenic mice." EJNMMI research vol. 5 (2015): 20. doi: https://doi.org/10.1186/s13550-015-0090-6
Yousefi BH, von Reutern B, Scherübl D, Manook A, Schwaiger M, Grimmer T, Henriksen G, Förster S, Drzezga A, Wester HJ. FIBT versus florbetaben and PiB: a preclinical comparison study with amyloid-PET in transgenic mice. EJNMMI Res. 2015 Mar 28;5:20. doi: 10.1186/s13550-015-0090-6. eCollection 2015. PMID: 25918674; PMCID: PMC4402683.
Copy Download .nbib Format: NLM
Improving efficiency management of radiopharmaceutical materials at a nuclear medicine department.

BMJ quality improvement reports

Al Ahmed A, Al-Surimi K.
PMID: 26734451
BMJ Qual Improv Rep. 2015 Sep 02;4(1). doi: 10.1136/bmjquality.u208970.w3709. eCollection 2015.

The cost of radiopharmaceutical materials is highly expensive compared with other resources employed in nuclear medicine department. Hence, inefficient utilization of these costly materials will lead to waste and more financial burden on the healthcare system, increasing the patient...

Cite
Al Ahmed A, Al-Surimi K. Improving efficiency management of radiopharmaceutical materials at a nuclear medicine department. BMJ Qual Improv Rep. 2015;4(1)doi: 10.1136/bmjquality.u208970.w3709.
Al Ahmed, A., & Al-Surimi, K. (2015). Improving efficiency management of radiopharmaceutical materials at a nuclear medicine department. BMJ quality improvement reports, 4(1), . https://doi.org/10.1136/bmjquality.u208970.w3709
Al Ahmed, Ali, and Al-Surimi, Khaled. "Improving efficiency management of radiopharmaceutical materials at a nuclear medicine department." BMJ quality improvement reports vol. 4,1 (2015). doi: https://doi.org/10.1136/bmjquality.u208970.w3709
Al Ahmed A, Al-Surimi K. Improving efficiency management of radiopharmaceutical materials at a nuclear medicine department. BMJ Qual Improv Rep. 2015 Sep 02;4(1). doi: 10.1136/bmjquality.u208970.w3709. eCollection 2015. PMID: 26734451; PMCID: PMC4693110.
Copy Download .nbib Format: NLM
Bone Targeted Therapies for Bone Metastasis in Breast Cancer.

Journal of clinical medicine

Razaq W.
PMID: 26237142
J Clin Med. 2013 Oct 14;2(4):176-87. doi: 10.3390/jcm2040176.

Cancer metastasis to the bone develops commonly in patients with various malignancies, and is a major cause of morbidity and diminished quality of life in many affected patients. Emerging treatments for metastatic bone disease have arisen from advances in...

Cite
Razaq W. Bone Targeted Therapies for Bone Metastasis in Breast Cancer. J Clin Med. 2013;2(4):176-87doi: 10.3390/jcm2040176.
Razaq, W. (2013). Bone Targeted Therapies for Bone Metastasis in Breast Cancer. Journal of clinical medicine, 2(4), 176-87. https://doi.org/10.3390/jcm2040176
Razaq, Wajeeha. "Bone Targeted Therapies for Bone Metastasis in Breast Cancer." Journal of clinical medicine vol. 2,4 (2013): 176-87. doi: https://doi.org/10.3390/jcm2040176
Razaq W. Bone Targeted Therapies for Bone Metastasis in Breast Cancer. J Clin Med. 2013 Oct 14;2(4):176-87. doi: 10.3390/jcm2040176. PMID: 26237142; PMCID: PMC4470142.
Copy Download .nbib Format: NLM
Neuroprotective Effects of Jitai Tablet, a Traditional Chinese Medicine, on the MPTP-Induced Acute Model of Parkinson's Disease: Involvement of the Dopamine System.

Evidence-based complementary and alternative medicine : eCAM

Liu J, Gao J, Tu S, Xu S, Liu Y, Shang W, Gu C, Huang Y, Han M.
PMID: 24799940
Evid Based Complement Alternat Med. 2014;2014:542383. doi: 10.1155/2014/542383. Epub 2014 Apr 02.

Jitai tablet (JTT) is a traditional Chinese medicine used to treat neuropsychiatric disorders. We previously demonstrated that JTT treatment led to increased level of dopamine transporter (DAT) in the striatum, thus indicating that JTT might have therapeutic potential for...

Cite
Liu J, Gao J, Tu S, et al. Neuroprotective Effects of Jitai Tablet, a Traditional Chinese Medicine, on the MPTP-Induced Acute Model of Parkinson's Disease: Involvement of the Dopamine System. Evid Based Complement Alternat Med. 2014;2014:542383doi: 10.1155/2014/542383.
Liu, J., Gao, J., Tu, S., Xu, S., Liu, Y., Shang, W., Gu, C., Huang, Y., & Han, M. (2014). Neuroprotective Effects of Jitai Tablet, a Traditional Chinese Medicine, on the MPTP-Induced Acute Model of Parkinson's Disease: Involvement of the Dopamine System. Evidence-based complementary and alternative medicine : eCAM, 2014542383. https://doi.org/10.1155/2014/542383
Liu, Jia, et al. "Neuroprotective Effects of Jitai Tablet, a Traditional Chinese Medicine, on the MPTP-Induced Acute Model of Parkinson's Disease: Involvement of the Dopamine System." Evidence-based complementary and alternative medicine : eCAM vol. 2014 (2014): 542383. doi: https://doi.org/10.1155/2014/542383
Liu J, Gao J, Tu S, Xu S, Liu Y, Shang W, Gu C, Huang Y, Han M. Neuroprotective Effects of Jitai Tablet, a Traditional Chinese Medicine, on the MPTP-Induced Acute Model of Parkinson's Disease: Involvement of the Dopamine System. Evid Based Complement Alternat Med. 2014;2014:542383. doi: 10.1155/2014/542383. Epub 2014 Apr 02. PMID: 24799940; PMCID: PMC3996930.
Copy Download .nbib Format: NLM
Knowledge about the availability of the pharmacist in the Nuclear Medicine Department: A questionnaire-based study among health-care professionals.

Journal of basic and clinical pharmacy

Parasuraman S, Mueen Ahmed KK, Bin Hashim TS, Muralidharan S, Kumar KJ, Ping WY, Syamittra B, Dhanaraj SA.
PMID: 25538467
J Basic Clin Pharm. 2014 Dec;6(1):19-23. doi: 10.4103/0976-0105.145773.

OBJECTIVE: The objective of this study was to analyze the knowledge about the availability of the pharmacist in the nuclear medicine department among health-care professionals through a prospective cohort study.METHODS: A total of 741 health-care professionals participated in the...

Cite
Parasuraman S, Mueen Ahmed KK, Bin Hashim TS, et al. Knowledge about the availability of the pharmacist in the Nuclear Medicine Department: A questionnaire-based study among health-care professionals. J Basic Clin Pharm. 2014;6(1):19-23doi: 10.4103/0976-0105.145773.
Parasuraman, S., Mueen Ahmed, K. K., Bin Hashim, T. S., Muralidharan, S., Kumar, K. J., Ping, W. Y., Syamittra, B., & Dhanaraj, S. A. (2014). Knowledge about the availability of the pharmacist in the Nuclear Medicine Department: A questionnaire-based study among health-care professionals. Journal of basic and clinical pharmacy, 6(1), 19-23. https://doi.org/10.4103/0976-0105.145773
Parasuraman, Subramani, et al. "Knowledge about the availability of the pharmacist in the Nuclear Medicine Department: A questionnaire-based study among health-care professionals." Journal of basic and clinical pharmacy vol. 6,1 (2014): 19-23. doi: https://doi.org/10.4103/0976-0105.145773
Parasuraman S, Mueen Ahmed KK, Bin Hashim TS, Muralidharan S, Kumar KJ, Ping WY, Syamittra B, Dhanaraj SA. Knowledge about the availability of the pharmacist in the Nuclear Medicine Department: A questionnaire-based study among health-care professionals. J Basic Clin Pharm. 2014 Dec;6(1):19-23. doi: 10.4103/0976-0105.145773. PMID: 25538467; PMCID: PMC4268625.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 1429 entries